Welcome to the OMA Blog
The Obesity Medicine Association Blog is the leading industry hub for obesity medicine. Find the latest research, expert insights, and practical tips to tackle the multifaceted disease of obesity. Hear from OMA Outreach Committee members, OMA Board members, and more to gain a deeper understanding of the complex factors influencing obesity and explore innovative approaches to prevention, treatment, and long-term management. Join a community of healthcare professionals, researchers, and individuals passionate about combating obesity.
View by Category
Obesity Management Foundations for the Primary Care Clinician
Collaborative course available from the AANP and the OMA.
Leading Obesity Expert Organizations Release Statement to Patients on Compounded GLP-1 Alternatives
Today, there's renewed optimism due to the emergence of GLP1-based drug therapies like Wegovy (semaglutide) and Zepbound (tirzepatide), which demonstrate remarkable effectiveness for weight and health. Unfortunately, many of the available alternatives, like compounded versions of semaglutide and tirzepatide, are not what they are advertised to be. These companies stated that they do not sell the active ingredient to compounding pharmacies, and substances made or distributed by compounding pharmacies or other healthcare practitioners that claim to be semaglutide (Wegovy, Ozempic) or tirzepatide (Zepbound, Mounjaro) have not been reviewed by the FDA for safety, quality, or efficacy. For more information, see the following details: Compounded peptides: An Obesity Medicine Association Position Statement - ScienceDirect | Obesity Medicine Association Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss | FDA Compounding and the FDA: Questions and Answers | FDA Open Letter Regarding the Use of Mounjaro® (tirzepatide) and Zepbound™ (tirzepatide) | Eli Lilly and Company Responsible Use Letter | Novo Nordisk Things You Should Know About Compounded Anti-Obesity (AOM) Medications | Obesity Medicine Association
Country’s Leading Obesity Expert Organizations Issue a Statement on the Full Results of the SELECT Study
The recent results of the SELECT Study published in the New England Journal of Medicine provide invaluable insights into the complex disease of obesity. The report has prompted several of the country’s leading obesity expert organizations, the Obesity Action Coalition (OAC), the Obesity Medicine Association (OMA), The Obesity Society (TOS), the American Society for Metabolic & Bariatric Surgery (ASMBS), and the STOP Obesity Alliance (STOP), to join together in issuing the following statement:
September OMA Member Highlight
Jennifer Seger, MD, FOMA became a fellow of the OMA in 2016. Read her full interview below to learn more about Dr. Seger and her…
Overcoming Obesity 2023 – Schedule Announcement
The agenda for Overcoming Obesity 2023 is now available to view! The Overcoming Obesity 2023 conference in San Antonio, TX, Oct 25-29 is the perfect…
Overcoming Obesity 2023 Featured Speaker Announced
Join OMA this October 25-29 in San Antonio, TX for Overcoming Obesity 2023. This conference is the perfect opportunity to network with fellow obesity medicine…
August OMA Member Highlight
Jerome Puryear, Jr., MD, DABOM, became an OMA member in 2019 and has made a great impact in his time here. He is an active…
2023 Annual Meeting of the American Medical Association (AMA) House of Delegates Report
Ethan Lazarus, MD, FOMA (Immediate Past-President of the OMA) attended the Annual AMA Meeting as the OMA delegate and Anthony Auriemma, MD, JD (Trustee, OMA…
July OMA Member Highlight
Initially, Kabir Harricharan Singh, MD became a member to get a discount on attending the Spring 2017 OMA Conference in Seattle, but once he realized…
Showing 1-9 of 15 results